Prosight Management’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-180,000
Closed -$4.99M 43
2026
Q1
$4.99M Sell
180,000
-447,162
-71% -$11.5M 0.82% 25
2025
Q4
$13.6M Sell
627,162
-708,338
-53% -$14M 2.81% 17
2025
Q3
$20.2M Sell
1,335,500
-473,039
-26% -$5.86M 4.71% 7
2025
Q2
$20.4M Sell
1,808,539
-17,624
-1% -$191K 4.97% 6
2025
Q1
$18.4M Buy
1,826,163
+326,163
+22% +$3.53M 6.05% 5
2024
Q4
$17.7M Sell
1,500,000
-221,512
-13% -$2.62M 4.9% 9
2024
Q3
$19.9M Sell
1,721,512
-278,488
-14% -$3.17M 4.89% 6
2024
Q2
$21.1M Buy
2,000,000
+140,000
+8% +$1.53M 6.32% 3
2024
Q1
$19.6M Buy
+1,860,000
New +$20.1M 5.45% 6

Other funds holding ROIV

Prosight Management's ROIV Position: Q2 2026 in Review

Prosight Management sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 180,000 shares — an estimated $4.99M sold.

Prosight Management first reported a position in ROIV in Q1 2024 and held it in 9 quarters. The position peaked at $21.1M in Q2 2024. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Prosight Management reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
  • Prosight Management sold 180,000 Roivant Sciences shares in Q2 2026, an estimated $4.99M.
  • Prosight Management first reported a position in Roivant Sciences in Q1 2024 and held it in 9 quarters.
  • Prosight Management's Roivant Sciences position peaked at $21.1M in Q2 2024.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.